28958-94-3 Usage
General Description
2-amino-3,4,5,6-tetrahydropyrimidine-4-carboxylic acid, also known as ACP, is a heterocyclic compound that contains a tetrahydropyrimidine ring. It is an important intermediate in the biosynthesis of thiamine (Vitamin B1), playing a crucial role in the formation of the thiazole moiety of the vitamin. ACP is also a key building block in the synthesis of certain thiamine analogs and has potential applications in the pharmaceutical industry. Additionally, ACP has been studied for its potential biological and pharmacological activities, showing promise as an anticonvulsant and neuroprotective agent. Its unique structure and versatile reactivity make ACP an interesting and valuable compound in various fields of research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 28958-94-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,9,5 and 8 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 28958-94:
(7*2)+(6*8)+(5*9)+(4*5)+(3*8)+(2*9)+(1*4)=173
173 % 10 = 3
So 28958-94-3 is a valid CAS Registry Number.
28958-94-3Relevant academic research and scientific papers
Facile solid phase synthesis of N-cycloguanidinyl-formyl peptides
Yang, Xiaoxiao,Bai, Guoliang,Lin, Hao,Wang, Dexin
supporting information, p. 1733 - 1735 (2014/03/21)
A novel strategy of solid phase synthesis of N-cycloguanidinyl-formyl peptides has been established and investigated which involved coupling orthogonal protected diaminoacid with resin bound peptide, α-amino group deprotection, guanidinylation of α-amino group by bis-Cbz-1H-pyrazole-1- carboxamidine followed by cleavage and cyclization in solution, and finally removing Cbz by palladium catalyzed hydrogenation. Through this method, cycloguanidine could be introduced to either N-terminus or sidechain of designated peptides. The reaction conditions were facile, straightforward, and totally adaptive to common solid phase peptide synthesis strategy.
